Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
Starlink Internet Remains Active in Iran Despite Nationwide Blackout 
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits 
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
BOULDER, Colo., March 28, 2017 -- Miragen Therapeutics, Inc. (Nasdaq:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA-targeted therapies, today announced that William S. Marshall, Ph.D., President and Chief Executive Officer, will provide a company overview at the Needham and Company 16th Annual Healthcare Conference on Tuesday, April 4, 2017, at 5:00 p.m. ET. The conference is being held at the Westin New York Grand Central hotel in New York City.
The presentation will be webcast live and may be accessed by visiting the "Investors" section of the Company’s web site at www.investors.miragentherapeutics.com. A replay of the webcast will be available for 90 days.
About Miragen Therapeutics, Inc.
Miragen Therapeutics, Inc. is a clinical-stage biopharmaceutical company discovering and developing proprietary RNA-targeted therapeutics with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. miRagen’s two lead product candidates, MRG-106 and MRG-201, are currently in Phase 1 clinical trials. miRagen’s clinical product candidate for the treatment of certain cancers, MRG-106, is an inhibitor of microRNA-155, which is found at abnormally high levels in several blood cancers. miRagen’s clinical product candidate for the treatment of pathological fibrosis, MRG-201, is a replacement for miR-29, which is found at abnormally low levels in a number of pathological fibrotic conditions, including cardiac, renal, hepatic, and pulmonary fibrosis, as well as systemic sclerosis. In addition to miRagen’s clinical programs, it is developing a pipeline of pre-clinical product candidates. The goal of miRagen’s translational medicine strategy is to progress rapidly to first in human studies once it has established the pharmacokinetics, pharmacodynamics and safety of the product candidate in pre-clinical studies. For more information, please visit www.miragentherapeutics.com.
For information on clinical trials please visit www.clinicaltrials.gov.
miRagen Investor Contact: Adam Levy Chief Business Officer (720) 407-4595 [email protected]
